Changing FDA Regulatory Environment Could Bolster Biotech, ‘BBH’

The Food & Drug Administration’s (FDA) recent green light of Biogen’s Alzheimer’s disease drug Aducanumab – the first new Alzheimer’s approval in roughly two decades – could be a sign the FDA is taking a new approach to approvals. That could benefit biotechnology stocks and exchange...